|Company name||Questcor Pharmaceuticals Inc|
|Live stock price||[stckqut]QCOR[/stckqut]|
|P/E compared to competitors||Good|
|Confident Investor Rating||Good|
|Target stock price (TWCA growth scenario)||$72.41|
|Target stock price (averages with growth)||$81.5|
|Target stock price (averages with no growth)||$38.76|
|Target stock price (manual assumptions)||$67|
The following company description is from Google Finance: http://www.google.com/finance?q=qcor
Questcor Pharmaceuticals, Inc. (Questcor) is a biopharmaceutical company. The Company is focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Its primary product is H.P. Acthar Gel (repository corticotropin injection), or Acthar, an injectable drug that is approved by the United States food and drug administration (FDA), for the treatment of 19 indications. Its research and development program is focused on: the evaluation of the use of Acthar for certain on-label indications; the investigation of other potential uses of Acthar for indications not FDA approved; and the expansion of its understanding of how Acthar works in the human body (pharmacology), and ultimately, its mechanisms of action in the disease states for which it is used, or may be used in the future. The Company sells Doral to pharmaceutical wholesalers, which resell Doral primarily to retail pharmacies and hospitals.
Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in this stock.
If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor.